Komori
Tsubota Laboratory (4890) · InitiativeRestated

Strengthening Regulatory Science Capabilities

First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2026.

3entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023 – FY20262023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Strengthening Regulatory Science CapabilitiesA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「To translate the results of research and development into approvals from regulatory authorities in Japan and other countries, including the Pharmaceuticals and Medical Devices Agency (PMDA), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and China's National Medical Products Administration (NMPA), and to achieve commercialization, strengthening capabilities in regulatory science is essential.」

    The company has reaffirmed its policy of strengthening the R&D Division's expertise with regulatory authorities in Japan and overseas in mind, leading to approvals and commercialization.
  2. FY2024RestatedAnnual report

    「Strengthening capabilities in regulatory science is essential to taking research and development through approval by the Pharmaceuticals and Medical Devices Agency (PMDA) and ultimately to commercialization. Based on this recognition, we are strengthening these capabilities, centered on the R&D Division, by subdividing the organization and securing personnel.」

    The company has reiterated its policy of strengthening its regulatory science capabilities through organizational specialization and personnel recruitment in preparation for approval and commercialization.
  3. FY2023First statedAnnual report

    「Strengthening capabilities in regulatory science is essential to taking research and development through approval by the Pharmaceuticals and Medical Devices Agency (PMDA) and ultimately to commercialization. Based on this recognition, we are strengthening these capabilities, centered on the R&D Division, by subdividing the organization and securing personnel.」

    For approval and commercialization, the company has for the first time identified as a standalone issue measures to strengthen its regulatory science capabilities through organizational specialization and personnel recruitment.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Tsubota Laboratory yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Regulatory Science Capabilities | Tsubota Laboratory Incorporated (4890) | Komori